Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000035298 | SCV000058946 | likely benign | not specified | 2012-09-24 | criteria provided, single submitter | clinical testing | 1000-14T>C in Intron 07 of GLA: This variant is not expected to have clinical si gnificance because it is not located within the splice consensus sequence. |
Fulgent Genetics, |
RCV002496526 | SCV002808143 | likely benign | Fabry disease | 2021-12-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002496526 | SCV003470414 | likely benign | Fabry disease | 2024-03-05 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV004703191 | SCV005210726 | likely benign | not provided | criteria provided, single submitter | not provided | ||
All of Us Research Program, |
RCV002496526 | SCV005426141 | uncertain significance | Fabry disease | 2024-06-17 | criteria provided, single submitter | clinical testing | This variant causes a T to C nucleotide substitution at the -14 position of intron 6 of the GLA gene. Splice site prediction tools are inconclusive regarding the impact of this variant on RNA splicing. To our knowledge, RNA studies have not been reported for this variant. This variant has not been reported in individuals affected with GLA-related disorders in the literature. This variant has been identified in 3/204206 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |